Mark Udell

Mark Udell currently serves as our Chief Financial Officer and previously served as our Chief Accounting Officer. Prior to that, Mark served as Chief Accounting Officer of CURE Pharmaceutical Holding Corp (“CPHC”) from 2018 until 2022 where he was an integral part of selling the pharmaceutical assets of CPHC for $20 million. From 2011 until 2018 Mark served as the Chief Financial Officer of CURE Pharmaceutical Corporation (“CPC”) where he was responsible for all public Securities and Exchange Commission filings, financial audits, accounting and assisted with financing transactions. From 2007 to 2011, he served as Chief Accounting Officer and Controller of InnoZen, Inc., another drug delivery company, where he was responsible for establishing, monitoring, and enforcing internal policies and procedures, as well as conducting audits and working with external auditors. Prior to Mark’s time at InnoZen, he served as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mark is a Certified Public Accountant with over 24 years of experience in finance and accounting and has gained valuable knowledge in the drug delivery industry during his time at CPHC, CPC and InnoZen. He is a key contributor to our development, operations and commercialization of various drug delivery technologies. He holds a B.S. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.